ranolazine

Details

Files
Generic Name:
ranolazine
Project Status:
Complete
Therapeutic Area:
Stable angina pectoris, adults
Manufacturer:
KYE Pharmaceuticals Inc.
Brand Name:
Corzyna
Project Line:
Reimbursement Review
Project Number:
SR0655-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies, including beta-blockers and calcium channel blockers.
Recommendation Type:
Do not reimburse
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input open July 17, 2020
Call for patient input closed September 08, 2020
Clarification:

- No patient input submission received

Submission received August 17, 2020
Submission accepted August 31, 2020
Review initiated September 01, 2020
Clarification:

- Selected for CADTH/INESSS Joint Clinician Engagement

Draft CADTH review report(s) provided to sponsor for comment November 17, 2020
Deadline for sponsors comments November 26, 2020
CADTH responses on draft review report(s) provided to sponsor January 08, 2021
Expert committee meeting (initial) January 20, 2021
Draft recommendation issued to sponsor February 01, 2021
End of embargo period February 16, 2021
Clarification:

- Reconsideration requested

Expert committee meeting May 19, 2021
Final recommendation issued to sponsor and drug plans May 27, 2021
Final recommendation posted May 31, 2021
Deadline for sponsor to submit redaction requests on draft CADTH review report(s) June 10, 2021
CADTH review report(s) posted August 06, 2021